<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04005404</url>
  </required_header>
  <id_info>
    <org_study_id>A 2018 0237</org_study_id>
    <nct_id>NCT04005404</nct_id>
  </id_info>
  <brief_title>Surgical Treatment of Hip Fractures Under Peripheral Regional Anesthesia</brief_title>
  <official_title>Surgical Treatment of Proximal Femoral Fractures Under Peripheral Regional Anesthesia. A Prospective Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helios Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helios Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates whether treatment of proximal femoral fractures is possible using a&#xD;
      peripheral regional anesthesia technique.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study investigates whether treatment of proximal femoral fractures is possible using a&#xD;
      peripheral regional anesthesia technique.&#xD;
&#xD;
      After positioning on the non-fractured side, a double injection technique is used (dual&#xD;
      guidance concept: nerve stimulation and sonography).&#xD;
&#xD;
      The injections are performed parasacrally (blockade of the sacral plexus under the piriformis&#xD;
      muscle) and lumbar paravertebrally (psoas compartment block and transmuscular quadratus&#xD;
      lumborum block). Per block 20 ml ropivacaine 0.375% is administered (total dose: 225mg&#xD;
      ropivacaine).&#xD;
&#xD;
      The study examines the success rate (rate of successfully performed nerve blockade; need for&#xD;
      supplemental medication: sufentanil and/or propofol; conversion rate to general anesthesia),&#xD;
      circulatory stability (need for application of ephedrine or norepinephrine) and side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Differentiated analysis for the subgroups &quot;subtrochanteric femoral fractures&quot;, &quot;intertrochanteric femoral fractures&quot; and &quot;neck femur fractures&quot;</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success Rate (Supplemental Medication)</measure>
    <time_frame>during surgery</time_frame>
    <description>number of participants with need for supplemental analgesic medication (sufentanil)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Success Rate (Conversion to General Anesthesia)</measure>
    <time_frame>during surgery</time_frame>
    <description>number of participants with need for conversion to general anesthesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulation Stability</measure>
    <time_frame>during surgery</time_frame>
    <description>number of participants with need for application of ephedrine and/or norepinephrine</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hip Fractures</condition>
  <arm_group>
    <arm_group_label>intertrochanteric femoral fractures</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>geriatric patients with intertrochanteric femoral fracture who have consented to the study intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neck femur fractures</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>geriatric patients with neck of femur fracture who have consented to the study intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subtrochanteric femoral fractures</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>geriatric patients with subtrochanteric femoral fracture who have consented to the study intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine (sciatic nerve block)</intervention_name>
    <description>injection of 20 ml ropivacaine 0.375%</description>
    <arm_group_label>intertrochanteric femoral fractures</arm_group_label>
    <arm_group_label>neck femur fractures</arm_group_label>
    <arm_group_label>subtrochanteric femoral fractures</arm_group_label>
    <other_name>parasacral sciatic nerve block (sacral plexus)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine (lumbar plexus block L2-L4)</intervention_name>
    <description>injection of 20 ml ropivacaine 0.375%</description>
    <arm_group_label>intertrochanteric femoral fractures</arm_group_label>
    <arm_group_label>neck femur fractures</arm_group_label>
    <arm_group_label>subtrochanteric femoral fractures</arm_group_label>
    <other_name>posts compartment block (lumbar plexus L2-L4)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine (lumbar plexus block Th12-L1)</intervention_name>
    <description>injection of 20 ml ropivacaine 0.375%</description>
    <arm_group_label>intertrochanteric femoral fractures</arm_group_label>
    <arm_group_label>neck femur fractures</arm_group_label>
    <arm_group_label>subtrochanteric femoral fractures</arm_group_label>
    <other_name>transmuscular quadratus lumborum block (lumbar plexus Th12-L1)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  proximal femoral fracture&#xD;
&#xD;
          -  older then 18 years&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  local or systematic inflammation&#xD;
&#xD;
          -  allergy to ropivacaine&#xD;
&#xD;
          -  participate in other studies&#xD;
&#xD;
          -  body mass index over 35&#xD;
&#xD;
          -  periprosthetic fractures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Helios Medical Center Schwerin, Department of Anesthesiology</name>
      <address>
        <city>Schwerin</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Adhikary SD, Short AJ, El-Boghdadly K, Abdelmalak MJ, Chin KJ. Transmuscular quadratus lumborum versus lumbar plexus block for total hip arthroplasty: A retrospective propensity score matched cohort study. J Anaesthesiol Clin Pharmacol. 2018 Jul-Sep;34(3):372-378. doi: 10.4103/joacp.JOACP_335_17.</citation>
    <PMID>30386022</PMID>
  </reference>
  <reference>
    <citation>Akkaya T, Comert A, Kendir S, Acar HI, Gumus H, Tekdemir I, Elhan A. Detailed anatomy of accessory obturator nerve blockade. Minerva Anestesiol. 2008 Apr;74(4):119-22.</citation>
    <PMID>18354367</PMID>
  </reference>
  <reference>
    <citation>Birnbaum K, Prescher A, Hessler S, Heller KD. The sensory innervation of the hip joint--an anatomical study. Surg Radiol Anat. 1997;19(6):371-5.</citation>
    <PMID>9479711</PMID>
  </reference>
  <reference>
    <citation>Coburn M, Sanders RD, Maze M, Nguyên-Pascal ML, Rex S, Garrigues B, Carbonell JA, Garcia-Perez ML, Stevanovic A, Kienbaum P, Neukirchen M, Schaefer MS, Borghi B, van Oven H, Tognù A, Al Tmimi L, Eyrolle L, Langeron O, Capdevila X, Arnold GM, Schaller M, Rossaint R; HIPELD Study Investigators. The hip fracture surgery in elderly patients (HIPELD) study to evaluate xenon anaesthesia for the prevention of postoperative delirium: a multicentre, randomized clinical trial. Br J Anaesth. 2018 Jan;120(1):127-137. doi: 10.1016/j.bja.2017.11.015. Epub 2017 Nov 21.</citation>
    <PMID>29397119</PMID>
  </reference>
  <reference>
    <citation>Duan X, Coburn M, Rossaint R, Sanders RD, Waesberghe JV, Kowark A. Efficacy of perioperative dexmedetomidine on postoperative delirium: systematic review and meta-analysis with trial sequential analysis of randomised controlled trials. Br J Anaesth. 2018 Aug;121(2):384-397. doi: 10.1016/j.bja.2018.04.046. Epub 2018 Jun 22.</citation>
    <PMID>30032877</PMID>
  </reference>
  <reference>
    <citation>Girón-Arango L, Peng PWH, Chin KJ, Brull R, Perlas A. Pericapsular Nerve Group (PENG) Block for Hip Fracture. Reg Anesth Pain Med. 2018 Nov;43(8):859-863. doi: 10.1097/AAP.0000000000000847.</citation>
    <PMID>30063657</PMID>
  </reference>
  <reference>
    <citation>Guay J, Parker MJ, Gajendragadkar PR, Kopp S. Anaesthesia for hip fracture surgery in adults. Cochrane Database Syst Rev. 2016 Feb 22;2:CD000521. doi: 10.1002/14651858.CD000521.pub3. Review.</citation>
    <PMID>26899415</PMID>
  </reference>
  <reference>
    <citation>Guay J, Parker MJ, Griffiths R, Kopp SL. Peripheral Nerve Blocks for Hip Fractures: A Cochrane Review. Anesth Analg. 2018 May;126(5):1695-1704. doi: 10.1213/ANE.0000000000002489. Review.</citation>
    <PMID>28991122</PMID>
  </reference>
  <reference>
    <citation>Johnston DF, Stafford M, McKinney M, Deyermond R, Dane K. Peripheral nerve blocks with sedation using propofol and alfentanil target-controlled infusion for hip fracture surgery: a review of 6 years in use. J Clin Anesth. 2016 Mar;29:33-9. doi: 10.1016/j.jclinane.2015.10.012. Epub 2016 Feb 2.</citation>
    <PMID>26897445</PMID>
  </reference>
  <reference>
    <citation>Nielsen TD, Moriggl B, Søballe K, Kolsen-Petersen JA, Børglum J, Bendtsen TF. A Cadaveric Study of Ultrasound-Guided Subpectineal Injectate Spread Around the Obturator Nerve and Its Hip Articular Branches. Reg Anesth Pain Med. 2017 May/Jun;42(3):357-361. doi: 10.1097/AAP.0000000000000587.</citation>
    <PMID>28263244</PMID>
  </reference>
  <reference>
    <citation>Sá M, Graça R, Reis H, Cardoso JM, Sampaio J, Pinheiro C, Machado D. [Superior gluteal nerve: a new block on the block?]. Braz J Anesthesiol. 2018 Jul - Aug;68(4):400-403. doi: 10.1016/j.bjan.2016.11.001. Epub 2017 May 24. Portuguese.</citation>
    <PMID>28551063</PMID>
  </reference>
  <reference>
    <citation>Sauter AR, Ullensvang K, Niemi G, Lorentzen HT, Bendtsen TF, Børglum J, Pripp AH, Romundstad L. The Shamrock lumbar plexus block: A dose-finding study. Eur J Anaesthesiol. 2015 Nov;32(11):764-70. doi: 10.1097/EJA.0000000000000265.</citation>
    <PMID>26426575</PMID>
  </reference>
  <reference>
    <citation>Short AJ, Barnett JJG, Gofeld M, Baig E, Lam K, Agur AMR, Peng PWH. Anatomic Study of Innervation of the Anterior Hip Capsule: Implication for Image-Guided Intervention. Reg Anesth Pain Med. 2018 Feb;43(2):186-192. doi: 10.1097/AAP.0000000000000701.</citation>
    <PMID>29140962</PMID>
  </reference>
  <reference>
    <citation>Taha AM. A simple and successful sonographic technique to identify the sciatic nerve in the parasacral area. Can J Anaesth. 2012 Mar;59(3):263-7. doi: 10.1007/s12630-011-9630-3. Epub 2011 Dec 3.</citation>
    <PMID>22139964</PMID>
  </reference>
  <reference>
    <citation>Ueshima H, Otake H, Lin JA. Ultrasound-Guided Quadratus Lumborum Block: An Updated Review of Anatomy and Techniques. Biomed Res Int. 2017;2017:2752876. doi: 10.1155/2017/2752876. Epub 2017 Jan 3. Review.</citation>
    <PMID>28154824</PMID>
  </reference>
  <reference>
    <citation>Van Waesberghe J, Stevanovic A, Rossaint R, Coburn M. General vs. neuraxial anaesthesia in hip fracture patients: a systematic review and meta-analysis. BMC Anesthesiol. 2017 Jun 28;17(1):87. doi: 10.1186/s12871-017-0380-9. Review.</citation>
    <PMID>28659127</PMID>
  </reference>
  <reference>
    <citation>White SM, Moppett IK, Griffiths R, Johansen A, Wakeman R, Boulton C, Plant F, Williams A, Pappenheim K, Majeed A, Currie CT, Grocott MP. Secondary analysis of outcomes after 11,085 hip fracture operations from the prospective UK Anaesthesia Sprint Audit of Practice (ASAP-2). Anaesthesia. 2016 May;71(5):506-14. doi: 10.1111/anae.13415. Epub 2016 Mar 4.</citation>
    <PMID>26940645</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <results_first_submitted>June 29, 2020</results_first_submitted>
  <results_first_submitted_qc>February 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2021</results_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helios Research Center</investigator_affiliation>
    <investigator_full_name>Dr.med.Ronald Seidel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Regional Anesthesia</keyword>
  <keyword>Ultrasonography</keyword>
  <keyword>Hip Fractures</keyword>
  <keyword>Lumbosacral Plexus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT04005404/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT04005404/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intertrochanteric Femoral Fractures</title>
          <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
        </group>
        <group group_id="P2">
          <title>Neck Femur Fractures</title>
          <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
        </group>
        <group group_id="P3">
          <title>Subtrochanteric Femoral Fractures</title>
          <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intertrochanteric Femoral Fractures</title>
          <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
        </group>
        <group group_id="B2">
          <title>Neck Femur Fractures</title>
          <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
        </group>
        <group group_id="B3">
          <title>Subtrochanteric Femoral Fractures</title>
          <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87" lower_limit="81.75" upper_limit="89.25"/>
                    <measurement group_id="B2" value="84" lower_limit="80.5" upper_limit="87"/>
                    <measurement group_id="B3" value="79" lower_limit="72" upper_limit="91"/>
                    <measurement group_id="B4" value="85" lower_limit="81" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Success Rate (Supplemental Medication)</title>
        <description>number of participants with need for supplemental analgesic medication (sufentanil)</description>
        <time_frame>during surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intertrochanteric Femoral Fractures</title>
            <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
          </group>
          <group group_id="O2">
            <title>Neck Femur Fractures</title>
            <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
          </group>
          <group group_id="O3">
            <title>Subtrochanteric Femoral Fractures</title>
            <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate (Supplemental Medication)</title>
          <description>number of participants with need for supplemental analgesic medication (sufentanil)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Success Rate (Conversion to General Anesthesia)</title>
        <description>number of participants with need for conversion to general anesthesia</description>
        <time_frame>during surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intertrochanteric Femoral Fractures</title>
            <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
          </group>
          <group group_id="O2">
            <title>Neck Femur Fractures</title>
            <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
          </group>
          <group group_id="O3">
            <title>Subtrochanteric Femoral Fractures</title>
            <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate (Conversion to General Anesthesia)</title>
          <description>number of participants with need for conversion to general anesthesia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Circulation Stability</title>
        <description>number of participants with need for application of ephedrine and/or norepinephrine</description>
        <time_frame>during surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intertrochanteric Femoral Fractures</title>
            <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
          </group>
          <group group_id="O2">
            <title>Neck Femur Fractures</title>
            <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
          </group>
          <group group_id="O3">
            <title>Subtrochanteric Femoral Fractures</title>
            <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
          </group>
        </group_list>
        <measure>
          <title>Circulation Stability</title>
          <description>number of participants with need for application of ephedrine and/or norepinephrine</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intertrochanteric Femoral Fractures</title>
          <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
        </group>
        <group group_id="E2">
          <title>Neck Femur Fractures</title>
          <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
        </group>
        <group group_id="E3">
          <title>Subtrochanteric Femoral Fractures</title>
          <description>Ropivacaine (sciatic nerve block): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block L2-L4): injection of 20 ml ropivacaine 0.375%&#xD;
Ropivacaine (lumbar plexus block Th12-L1): injection of 20 ml ropivacaine 0.375%</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ventricular tachycardia</sub_title>
                <description>ventricular tachycardia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>heart failure</sub_title>
                <description>heart failure</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <description>myocardial infarction</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>epidural anesthesia</sub_title>
                <description>unintentional epidural anesthesia after lumbar plexus block</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>delirium</sub_title>
                <description>postoperative delirium</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>kidney injury</sub_title>
                <description>acute or acute-on-chronic kidney injury</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <description>urinary tract infection</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>Pneumonia</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director Prof. Dr. Petra Thürmann</name_or_title>
      <organization>Helios Center for Research and Innovation</organization>
      <phone>0049 (0)202 896-1851</phone>
      <email>petra.thuermann@helios-gesundheit.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

